3 Undervalued Biotechnology Stocks for Thursday, August 20
Discover the top 3 undervalued Biotechnology stocks for Thursday, August 20 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Commentary & Analysis
3 Undervalued Biotechnology Stocks for Tuesday, July 14
Discover the top 3 undervalued Biotechnology stocks for Tuesday, July 14 based on AAII’s Stock Grades.Tudor Pop
Why Amarin Corporation plc’s (AMRN) Stock Is Up 5.30%
As of Monday, June 22, Amarin Corporation plc’s AMRN share price has surged by 5.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
3 Undervalued Biotechnology Stocks for Thursday, June 11
Discover the top 3 undervalued Biotechnology stocks for Thursday, June 11 based on AAII’s Stock Grades.Tudor Pop
3 Undervalued Biotechnology Stocks for Monday, April 27
Discover the top 3 undervalued Biotechnology stocks for Monday, April 27 based on AAII’s Stock Grades.Tudor Pop
Financial Summary
| Share Statistics | AMRN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $297.0 | $286.3 | 31% |
|
| Shares Out (Mil) | 20.8 | 54.2 | 31% |
|
| Institutional Ownership | 88.5% | 92.8% | 56% |
|
| Float (Mil) | 19.0 | 39.7 | 28% |
|
| Beta | 0.80 | 0.94 | 48% |
|
| Avg Daily Volume (000s) | 48 | 534 | 28% |
|
| Price Change (52-week) |
(11.1%) | 58.7% | 36% |
|
| Growth | AMRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (19.0%) | 13.6% | 3% |
|
| Net Income (5yr) | (16.6%) | (10.1%) | 24% |
|
| EPS (5yr) | (13.3%) | 16.0% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.2% | (15.6%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.010) | ($0.070) | ($0.060) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.310) | ($0.020) | $0.980 | |
| Year/Year Chg | (97.5%) | (96.3%) | (96.8%) | |
| Financials | AMRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $186 | $37 | 31% |
|
| Net Income (TTM) (Mil) | ($27) | ($43) | 21% |
|
| EPS (TTM) | ($1.299) | ($1.400) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | $16 | ($31) | 40% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $160 | 2% |
|
| Valuation | AMRN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.67 | 2.77 | 12% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AMRN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 42.0% | 64.2% | 52% |
|
| Net Margin | (14.6%) | (75.9%) | 18% |
|
| ROA | (4.2%) | (47.3%) | 31% |
|
| ROE | (6.0%) | (55.0%) | 30% |
|
| Liabilities to Assets | 28.9% | 29.6% | 20% |
|
| F-Score | 5 | 2 | 50% |
|
Amarin Corporation plc did not pass any screens on 8/20/2026.
